In NF1-MET tumors, doxorubicin treatment caused a significant decrease in tumor growth (Figure 5A; p < 0.0005); however, doxorubicin treatment was inferior to capmatinib or trametinib (Figure 5B). The gene discussed is NF1; the disease is neoplasm.